Literature DB >> 31524272

Identification of the role of TRPM8 in glioblastoma and its effect on proliferation, apoptosis and invasion of the U251 human glioblastoma cell line.

Jianping Zeng1, Ye Wu1, Siyi Zhuang2, Liping Qin3, Shushan Hua2, Rajneesh Mungur1, Jianwei Pan1, Yu Zhu1, Renya Zhan1.   

Abstract

Glioblastoma multiforme (GBM) is the most commonly occurring brain cancer, and is characterized by its poor patient outcomes. The present study examined the mRNA expression levels of the transient receptor potential melastatin (TRPM) family in various types of cancer using the ONCOMINE database, along with their corresponding expression profiles in an array of cancer cell lines based on the Cancer Cell Line Encyclopedia (CCLE) datasets. Kaplan‑Meier plotter survival analysis via the Chinese Glioma Genome Atlas (CGGA) database was also used to evaluate the prognostic value of transient receptor potential melastatin 8 (TRPM8). For the activity test on the TRPM8 channel, patch‑clamp recordings and Ca2+ measurements by fluorescence imaging of Fluo‑4am were performed. Short hairpin RNA (shRNA) targeting TRPM8 was designed, synthesized and then transfected into the U251 cells via Lipofectamine 2000. The expression of extracellular singnal‑regulated kinase (ERK), cyclin D1 and Bcl‑2 were detected by performing western blotting and immunofluorescence. The apoptosis, proliferation and invasion of glioma cells were detected by using flow cytometry, and CCK‑8 and Transwell invasion assays. In the present study, TRPM8 was distinctively upregulated in GBM cell lines. TRPM8 is functional and has the characteristic of outward rectification, which was verified via electrophysiology and Ca2+ fluorescence imaging in U251 cells. The western blot and immunofluorescence results revealed that the expression of ERK, cyclin D1 and Bcl‑2 were decreased in the shRNA interference group. The CCK‑8 assay demonstrated that the proliferation ability of U251 cells in the U251/TRPM8 group was higher than that in the U251 group and U251/Con group (P<0.05). The result of the Transwell invasion assay indicated that the invasion of human glioblastoma U251 cells was positively correlated with the expression level of TRPM8. Collectively, the results of the present study indicated that Ca2+‑permeable TRPM8 nonselective cation channels contribute to survival, proliferation, apoptosis, and local tumor invasion of glioblastoma. Therefore, TRPM8 is a promising biomarker for aggressiveness of GBM, and a potential target in future anti‑glioblastoma therapies.

Entities:  

Year:  2019        PMID: 31524272     DOI: 10.3892/or.2019.7260

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  High Levels of HIST1H2BK in Low-Grade Glioma Predicts Poor Prognosis: A Study Using CGGA and TCGA Data.

Authors:  Weidong Liu; Zhentao Xu; Jie Zhou; Shuang Xing; Zhiqiang Li; Xu Gao; Shiyu Feng; Yilei Xiao
Journal:  Front Oncol       Date:  2020-05-08       Impact factor: 6.244

2.  A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.

Authors:  Michelle Zalles; Nataliya Smith; Debra Saunders; Megan Lerner; Kar-Ming Fung; James Battiste; Rheal A Towner
Journal:  J Cell Mol Med       Date:  2021-12-14       Impact factor: 5.310

3.  ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.

Authors:  Michelle Zalles; Nataliya Smith; Debra Saunders; Mayra Guzman; Megan Lerner; Kar-Ming Fung; Anish Babu; James Battiste; Junho Chung; Kyusang Hwang; Junyeong Jin; Rheal A Towner
Journal:  Neurooncol Adv       Date:  2021-09-17

Review 4.  A novel strategy for treating cancer: understanding the role of Ca2+ signaling from nociceptive TRP channels in regulating cancer progression.

Authors:  Wen-Li Hsu; Mami Noda; Tohru Yoshioka; Etsuro Ito
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

Review 5.  Mechanisms of Invasion in Glioblastoma: Extracellular Matrix, Ca2+ Signaling, and Glutamate.

Authors:  Jae-Seon So; Hyeono Kim; Kyung-Seok Han
Journal:  Front Cell Neurosci       Date:  2021-06-02       Impact factor: 5.505

6.  Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.

Authors:  Michelle Zalles; Nataliya Smith; Jadith Ziegler; Debra Saunders; Shannon Remerowski; Lincy Thomas; Rafal Gulej; Nadya Mamedova; Megan Lerner; Kar-Ming Fung; Junho Chung; Kyusang Hwang; Junyeong Jin; Graham Wiley; Chase Brown; James Battiste; Jonathan D Wren; Rheal A Towner
Journal:  J Cell Mol Med       Date:  2019-12-21       Impact factor: 5.310

7.  Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy.

Authors:  Mike-Andrew Westhoff; Marie Schuler-Ortoli; Daniela Zerrinius; Amina Hadzalic; Andrea Schuster; Hannah Strobel; Angelika Scheuerle; Tiana Wong; Christian Rainer Wirtz; Klaus-Michael Debatin; Aurelia Peraud
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.